OptimalDosages.com publishes reference material for laboratory and educational use. Nothing here is medical advice, a prescription, or a recommendation for human administration.
By continuing you confirm you are 21 or older and that you are accessing this material in a research or educational capacity.
Mitochondrial ORF of the 12S rRNA type-c. Work out exactly what to draw for your own mix, see the doses used in research, and follow a week-by-week plan. Evidence tier: preclinical.
| When | Dose | How Often | How Many mL | Draw To | Number Of Doses | Peptide Used |
|---|---|---|---|---|---|---|
| Low reported | 5 mg | 2–3× weekly | 0.125 mL | 12.5 u | 8 doses | |
| Standard | 10 mg | 2–3× weekly | 0.25 mL | 25 u | 4 doses | |
| Research study dose | 0.5–5 mg/kg weight-based | daily | Set by body weight — can't be turned into a single amount to draw | |||
| Level | Dose | How Often | How Many mL | Draw To | Doses In Vial | |
|---|---|---|---|---|---|---|
| Weeks 1–2 | 5 mg | 2.5× weekly | 0.125 mL | 12.5 u | 5 | 25 mg |
| Week 3 onward per 4 weeks from here on |
10 mg | 2.5× weekly | 0.25 mL | 25 u | 10 | 100 mg |
A mitochondrial-derived peptide acting via AMPK on insulin sensitivity and metabolic homeostasis. Genuinely interesting mechanism with solid research data and human observational correlations, but no human dosing trials.
Buy MOTS-cthis peptideOpens optimal-pep.com in a new tab
Browse the full catalogue, or jump to a neighbouring compound.
A coenzyme rather than a peptide. Direct NAD+ administration is bioavailability-limited and often poorly tolerated (stinging, flus…
A cardiolipin-targeting mitochondrial peptide — the only compound in this class with substantial registered human trial data, acro…
Every compound compared in one table: dose range, how often, half-life and evidence tier.